论文部分内容阅读
子宫内膜癌晚期患者及具有高危因素的早期患者易发生转移及复发,预后较差,对这些患者的辅助治疗包括化疗、放疗、激素治疗等,但治疗效果并不理想且毒性较大。近年来免疫疗法成为肿瘤治疗的新热点,其中以程序性死亡受体1/程序性死亡配体1(PD-1/PD-L1)为靶点的免疫治疗药物在临床实验中显示出了较好的疗效和耐受性,本文将对PD-1/PD-L1的生物学结构、在子宫内膜癌发生发展中的作用,以及PD-1/PD-L1抑制剂在子宫内膜癌中的应用前景进行综述。
Patients with advanced endometrial cancer and early-stage patients with high risk factors are prone to metastasis and recurrence with poor prognosis. Adjuvant treatment for these patients includes chemotherapy, radiotherapy and hormone therapy, but the treatment effect is not ideal and the toxicity is relatively high. In recent years, immunotherapy has become a new hot spot in cancer treatment. Among them, the immunotherapy drugs targeting PD-1 / PD-L1 have been shown to be more effective in clinical trials Good curative effect and tolerability, this article will study the biological structure of PD-1 / PD-L1, its role in the development of endometrial carcinoma, and the role of PD-1 / PD-L1 in endometrial carcinoma The application prospect is summarized.